Prashant Kumar The life sciences industry is currently navigating a seismic shift as Generative AI transitions from a theoretical novelty to a core operational tool. We are witnessing the dawn of the “Automated Scientist,” capable of synthesizing vast datasets and drafting complex documents in a fraction of the time required by traditional methods. However, beneath the surface … Read more
In the rapidly evolving landscape of drug development, the static boundaries of frequentist statistics are finally being challenged by a more dynamic, iterative framework. For years, Bayesian approaches remained at the periphery of drug approvals, often relegated to early-phase dose-finding or exploratory sub-studies. A new FDA guidance changes the calculus, providing a formal roadmap for … Read more
The FDA Commissioner’s recent announcement streamlining the Investigational New Drug (IND) process is a breath of fresh air for an industry often suffocated by its own data. By proposing a reduction in the non-safety-related requirements for early-stage applications, the Agency is signaling a pivot toward common sense in clinical entry. For those of us in … Read more
For decades, the Limulus Amebocyte Lysate (LAL) test has served as the gold standard for detecting bacterial endotoxins, yet evolving manufacturing complexities demand a more nuanced regulatory approach. The FDA’s updated guidance on pyrogen and endotoxin testing marks a significant shift, bridging the gap between legacy methodologies and modern analytical capabilities. As product portfolios expand … Read more
Although 3D printing for drugs and biologics still has ways to go to become common, the FDA and EMA have been receptive to proposal for products using this technology. As 3D printing (3DP) moves from rapid prototyping to the mass customization of solid oral dosage forms, regulatory frameworks are rapidly evolving to catch up with … Read more
The FDA’s transition to the Adverse Event Monitoring System (AEMS) represents a fundamental shift from fragmented legacy databases to a centralized, cross-center regulatory architecture. This modernization effort consolidates disparate reporting streams for drugs, biologics, and medical devices into a singular analytical interface designed to enhance signal detection and data accessibility. For industry leadership, this evolution … Read more
The FDA’s long-anticipated transition toward human-centric predictive toxicology has reached a pivotal milestone with the release of the March 2026 draft guidance on New Approach Methodologies (NAMs). This document provides the high-level validation framework necessary for sponsors to move away from legacy animal dependencies and toward scientifically robust, in vitro and in silico alternatives. For … Read more
The FDA’s recent release of two guidance documents for developing biosimilars signals a critical shift toward regulatory efficiency. For senior management and regulatory affairs leads, these documents clarify the Agency’s move to reduce redundant clinical testing and streamline the use of global comparator data. Understanding these nuances is essential for optimizing development timelines and capital … Read more
Following the issuance of a Form FDA 483, the window for regulatory advocacy is brief and high-stakes, necessitating a response that serves as a cornerstone for future enforcement decisions. While the industry has long relied on historical precedent and unofficial best practices, the March 2026 draft guidance finally formalizes the Agency’s expectations for post-inspection communication. … Read more
In pharmaceutical development, regulatory exclusivity can create a powerful competitive moat—often determining whether an innovative lifecycle strategy translates into meaningful market differentiation. The U.S. Food and Drug Administration (FDA) has released a draft guidance providing long-awaited clarity on the statutory and regulatory framework governing three-year exclusivity under the Hatch-Waxman Amendments. For regulatory affairs leaders, portfolio … Read more
